CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus
CereVasc completed an $85 million Series C financing led by Piper Sandler Merchant Banking, with strategic participation from Johnson & Johnson Innovation and Medtronic. The capital will fund the conclusion of the STRIDE pivotal trial for its eShunt System, support regulatory work toward an FDA PMA submission, and prepare for US commercialization.
Key figures
- Deal Value Usd
- 85000000
- Trial name
- STRIDE
- Financing round
- Series C
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.